Newbury Pharmaceuticals AB (OSTO:NEWBRY) Total Receivables: kr26.29 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NEWBRY Newbury Pharmaceuticals AB OSTO:NEWBRY
41 GF Score
Price kr2.48
GF Value kr3.20
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Total Receivables?

Newbury Pharmaceuticals AB OSTO:NEWBRY -4.62% 41 Total Receivables is kr26.29 Mil as of Feb. 2026. GuruFocus rates OSTO:NEWBRY with a GF Score™ of 41/100 and a GF Value™ of kr3.20 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Newbury Pharmaceuticals AB's Total Receivables for the quarter that ended in Feb. 2026 was kr26.29 Mil.

Newbury Pharmaceuticals AB Total Receivables Related Terms

Newbury Pharmaceuticals AB Total Receivables Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Total Receivables Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Total Receivables
2.62 1.37 16.60 23.68 22.90

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.06 25.63 22.90 28.57 26.29
OSTO:NEWBRY
41GF Score
Newbury Pharmaceuticals AB OSTO:NEWBRY
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of kr26.29 Mil mean?
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Total Receivables of kr26.29 Mil as of Feb. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Total Receivables too high?
Newbury Pharmaceuticals AB's current Total Receivables is kr26.29 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Total Receivables compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Total Receivables of kr26.29 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Total Receivables is kr26.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Total Receivables is kr26.29 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Total Receivables is kr26.29 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20. GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.

Key valuation signals for OSTO:NEWBRY:

  • Total Receivables: kr26.29 Mil
  • GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges P52:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for OSTO:NEWBRY

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.48
Price
kr3.20
GF Value